Drug profile · INN
doxorubicin hydrochloride
CELDOXOME PEGYLATED LIPOSOMAL
doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) is a dna topoisomerase ii alpha inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — doxorubicin hydrochloride
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 19
- Data quality
- 0.89
Quick answer
doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) is a dna topoisomerase ii alpha inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase II alpha inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is doxorubicin hydrochloride?
doxorubicin hydrochloride (CELDOXOME PEGYLATED LIPOSOMAL) is a dna topoisomerase ii alpha inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for doxorubicin hydrochloride?
CELDOXOME PEGYLATED LIPOSOMAL is a marketed brand name for doxorubicin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of doxorubicin hydrochloride?
doxorubicin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.